Olaniyi Azeez Soetan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olaniyi Azeez Soetan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Adesola A. Oniyide
Cardiometabolic Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
1 shared publication- Ayodeji Folorunsho Ajayi
Department of Physiology, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
1 shared publication Ayodele O. Soladoye
Cardiometabolic Research Unit, Department of Physiology, College of Health Sciences, Bowen University, Iwo, Nigeria
1 shared publication- Ayomide Jonathan Jegede1 shared publication
Chinaza Dibia
HOPE Cardiometabolic Research Team & Department of Physiology, University of Ilorin, Ilorin, Nigeria; Department of Physiology, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria
1 shared publicationDamilare E. Areola
HOPE Cardiometabolic Research Team & Department of Physiology, University of Ilorin, Ilorin, Nigeria; Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria
1 shared publication
Latest Publications
- Open Access
- 26 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular pathology in PCOS. Objective: This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact to promote cardiovascular complications in women with PCOS while identifying potential therapeutic targets and areas requiring further investigation. Methods: A comprehensive review of clinical and experimental studies was conducted using PubMed, Scopus, and Web of Science databases. Relevant literature exploring mitochondrial alterations, oxidative stress, inflammatory cytokines, and endothelial function in PCOS, with emphasis on cardiovascular outcomes, was critically evaluated and summarized. Results: Women with PCOS exhibit altered mitochondrial dynamics, reduced ATP production, and elevated reactive oxygen species (ROS), which collectively impair vascular function. These mitochondrial abnormalities compromise oocyte quality and endometrial receptivity and activate proinflammatory signaling pathways, including the NLRP3 inflammasome, contributing to endothelial dysfunction and atherogenesis, and increased long‐term cardiovascular risk, particularly in women with prior pregnancy complications. Elevated levels of cytokines including TNF‐ α , IL‐6, and CRP further exacerbate cardiovascular risk. This bidirectional relationship between mitochondrial dysfunction and inflammation establishes a vicious cycle underlying cardiovascular deterioration in PCOS. Conclusion: Mitochondrial dysfunction and inflammation are interdependent mechanisms that contribute substantially to cardiovascular risk in women with PCOS. Targeting mitochondrial dysfunction and systemic inflammation presents a promising therapeutic strategy for reducing cardiovascular morbidity in PCOS. Future research should emphasize phenotype‐specific interventions, biomarker discovery, and translational trials to improve long‐term reproductive and cardiovascular outcomes.
- 26 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1)
Open AccessCardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular pathology in PCOS. Objective: This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact to promote cardiovascular complications in women with PCOS while identifying potential therapeutic targets and areas requiring further investigation. Methods: A comprehensive review of clinical and experimental studies was conducted using PubMed, Scopus, and Web of Science databases. Relevant literature exploring mitochondrial alterations, oxidative stress, inflammatory cytokines, and endothelial function in PCOS, with emphasis on cardiovascular outcomes, was critically evaluated and summarized. Results: Women with PCOS exhibit altered mitochondrial dynamics, reduced ATP production, and elevated reactive oxygen species (ROS), which collectively impair vascular function. These mitochondrial abnormalities compromise oocyte quality and endometrial receptivity and activate proinflammatory signaling pathways, including the NLRP3 inflammasome, contributing to endothelial dysfunction and atherogenesis, and increased long‐term cardiovascular risk, particularly in women with prior pregnancy complications. Elevated levels of cytokines including TNF‐ α , IL‐6, and CRP further exacerbate cardiovascular risk. This bidirectional relationship between mitochondrial dysfunction and inflammation establishes a vicious cycle underlying cardiovascular deterioration in PCOS. Conclusion: Mitochondrial dysfunction and inflammation are interdependent mechanisms that contribute substantially to cardiovascular risk in women with PCOS. Targeting mitochondrial dysfunction and systemic inflammation presents a promising therapeutic strategy for reducing cardiovascular morbidity in PCOS. Future research should emphasize phenotype‐specific interventions, biomarker discovery, and translational trials to improve long‐term reproductive and cardiovascular outcomes.
- Open Access
- 5 January 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 9
The role of nanotechnology in male fertility assessment
- 5 January 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 9
Open AccessThe role of nanotechnology in male fertility assessment
- Open Access
- 1 January 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 133, 110994
Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats
- 1 January 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 133, 110994
Open AccessSodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats